
    
      This is a single center, randomized, double-blind, placebo controlled clinical trial.

      Eligibility criteria:

        1. moderate-to-severe COPD patients

        2. aged 40-80 years,

        3. abstaining from cigarette smoking or maintaining a stable dose of cigarette consumption,

        4. no acute exacerbation of COPD,

        5. clinically being stable for one month and longer,

        6. not undergoing exercise training program.

      Primary endpoint:

      six-minute walk distance in meters at week 12.
    
  